Cover Image
市場調查報告書

葡萄薄膜炎 : 開發中產品分析

Uveitis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 219766
出版日期 內容資訊 英文 186 Pages
訂單完成後即時交付
價格
Back to Top
葡萄薄膜炎 : 開發中產品分析 Uveitis - Pipeline Review, H1 2017
出版日期: 2017年04月28日 內容資訊: 英文 186 Pages
簡介

所謂葡萄膜炎是指葡萄膜(眼球中間層──虹膜·睫狀體·脈胳膜)的發炎和刺激作用。有單眼或雙眼同時發病的可能性。發病的原因有自體免疫障礙(類風濕性關節炎,強直性脊椎症及其他)和感染疾病,以及曝露在毒素下等。主要的症狀有視力降低、飛蚊症、眼球痛、充血、畏光等。容易罹病的危險因子有受感染或自體免疫/發炎性疾病、眼睛外傷病史等。主要的治療方法有類固醇系眼藥和抗發炎劑,抗生素,抗病毒藥物等。

本報告提供全球各國治療葡萄薄膜炎所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

葡萄薄膜炎概要

治療藥的開發

  • 葡萄薄膜炎開發中產品:概要
  • 各企業開發中的葡萄薄膜炎治療藥
  • 大學/研究機關研究中的葡萄薄膜炎治療藥
  • 葡萄薄膜炎治療藥:開發中的產品一覽(各企業)
  • 葡萄薄膜炎治療藥:研究中的產品一覽(各大學/研究機關)

葡萄薄膜炎:治療藥的評估

  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

葡萄薄膜炎開發治療藥的企業

  • 2-BBB Medicines BV
  • Aciont Inc
  • Aldeyra Therapeutics Inc
  • Apitope International NV
  • Astellas Pharma Inc
  • Bionomics Ltd
  • Bristol-Myers Squibb Company
  • Can-Fite BioPharma Ltd
  • Clearside BioMedical Inc
  • Coherus BioSciences Inc
  • Elasmogen Ltd
  • Endocyte Inc
  • Enzo Biochem Inc
  • EyeGate Pharmaceuticals Inc
  • Eyevensys SAS
  • F. Hoffmann-La Roche Ltd
  • HanAll Biopharma Co Ltd
  • Icon Bioscience Inc
  • Idera Pharmaceuticals Inc
  • InnoMedica Holding AG
  • KPI Therapeutics Inc
  • Midatech Pharma Plc
  • Mitotech SA
  • Nemus Bioscience Inc
  • Neuroptis Biotech
  • Novartis AG
  • Oculis ehf
  • OncoNOx ApS
  • Orchid Pharma Ltd
  • OSE Immunotherapeutics
  • Palatin Technologies Inc
  • Panacea Biotec Ltd
  • Panoptes Pharma GesmbH
  • Pfizer Inc
  • pSivida Corp
  • Re-Pharm Ltd
  • Regeneron Pharmaceuticals Inc
  • Sandoz International GmbH
  • Santen Pharmaceutical Co Ltd
  • SynDevRx Inc
  • TxCell SA

藥物簡介

葡萄薄膜炎治療藥:開發暫停的產品

葡萄薄膜炎治療藥:開發中止的產品

葡萄薄膜炎相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9214IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveitis - Pipeline Review, H1 2017, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 8, 5, 2, 29, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Uveitis - Overview
    • Uveitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Uveitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Uveitis - Companies Involved in Therapeutics Development
    • 2-BBB Medicines BV
    • Aciont Inc
    • Aldeyra Therapeutics Inc
    • Apitope International NV
    • Astellas Pharma Inc
    • Bionomics Ltd
    • Bristol-Myers Squibb Company
    • Can-Fite BioPharma Ltd
    • Clearside BioMedical Inc
    • Coherus BioSciences Inc
    • Elasmogen Ltd
    • Endocyte Inc
    • Enzo Biochem Inc
    • EyeGate Pharmaceuticals Inc
    • Eyevensys SAS
    • F. Hoffmann-La Roche Ltd
    • HanAll Biopharma Co Ltd
    • Icon Bioscience Inc
    • Idera Pharmaceuticals Inc
    • InnoMedica Holding AG
    • KPI Therapeutics Inc
    • Midatech Pharma Plc
    • Mitotech SA
    • Nemus Bioscience Inc
    • Neuroptis Biotech
    • Novartis AG
    • Oculis ehf
    • OncoNOx ApS
    • Orchid Pharma Ltd
    • OSE Immunotherapeutics
    • Palatin Technologies Inc
    • Panacea Biotec Ltd
    • Panoptes Pharma GesmbH
    • Pfizer Inc
    • pSivida Corp
    • Re-Pharm Ltd
    • Regeneron Pharmaceuticals Inc
    • Sandoz International GmbH
    • Santen Pharmaceutical Co Ltd
    • SynDevRx Inc
    • TxCell SA
  • Uveitis - Drug Profiles
    • 2B-3201 - Drug Profile
    • abatacept - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • ADX-102 - Drug Profile
    • Antisense Oligonucleotide to Inhibit NLRP3 for Uveitis, Cystitis and Inflammatory Disorders - Drug Profile
    • Antisense RNAi Oligonucleotide to Inhibit ProRenin Receptor for Uveitis and Diabetic Retinopathy - Drug Profile
    • ANV-103 - Drug Profile
    • ATXUV-1 - Drug Profile
    • B27-PD - Drug Profile
    • BNC-164 - Drug Profile
    • celecoxib - Drug Profile
    • Col-Treg - Drug Profile
    • CVX-001 - Drug Profile
    • cyclosporine SR - Drug Profile
    • dalazatide - Drug Profile
    • dexamethasone acetate - Drug Profile
    • dexamethasone acetate - Drug Profile
    • dexamethasone acetate - Drug Profile
    • dexamethasone sodium phosphate - Drug Profile
    • Drug for Chronic Uveitis - Drug Profile
    • Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile
    • EBI-031 - Drug Profile
    • EC-1669 - Drug Profile
    • ELN-21 - Drug Profile
    • ELN-22 - Drug Profile
    • EYS-606 - Drug Profile
    • fluocinolone acetonide SR - Drug Profile
    • FR-104 - Drug Profile
    • Gene Therapy for Dry Age-Related Macular Degeneration and Uveitis - Drug Profile
    • HL-036 - Drug Profile
    • HO-10 - Drug Profile
    • IVMED-10 - Drug Profile
    • IVMED-20 - Drug Profile
    • KPI-190 - Drug Profile
    • latanoprost SR - Drug Profile
    • LME-636 - Drug Profile
    • lodamin - Drug Profile
    • methotrexate - Drug Profile
    • NB-2222 - Drug Profile
    • NOP-3 - Drug Profile
    • OX-1001 - Drug Profile
    • piclidenoson - Drug Profile
    • PL-8177 - Drug Profile
    • plastoquinone decyl triphenylphosphonium bromide - Drug Profile
    • PP-001 - Drug Profile
    • PPL-003 - Drug Profile
    • RP-0217 - Drug Profile
    • sarilumab - Drug Profile
    • sirolimus - Drug Profile
    • Small Molecule to Inhibit PDE4B and TNF Alpha for Asthma, COPD and Uveitis - Drug Profile
    • Small Molecules for Posterior Uveitis - Drug Profile
    • Small Molecules to Inhibit 5-Lipoxygenase for Uveitis - Drug Profile
    • Small Molecules to Inhibit TYK2 for Psoriasis and Uveitis - Drug Profile
    • Stem Cell Therapy for Autoimmune Diseases - Drug Profile
    • tesidolumab - Drug Profile
    • triamcinolone acetonide - Drug Profile
  • Uveitis - Dormant Projects
  • Uveitis - Discontinued Products
  • Uveitis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Uveitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Uveitis - Pipeline by 2-BBB Medicines BV, H1 2017
  • Uveitis - Pipeline by Aciont Inc, H1 2017
  • Uveitis - Pipeline by Aldeyra Therapeutics Inc, H1 2017
  • Uveitis - Pipeline by Apitope International NV, H1 2017
  • Uveitis - Pipeline by Astellas Pharma Inc, H1 2017
  • Uveitis - Pipeline by Bionomics Ltd, H1 2017
  • Uveitis - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Uveitis - Pipeline by Can-Fite BioPharma Ltd, H1 2017
  • Uveitis - Pipeline by Clearside BioMedical Inc, H1 2017
  • Uveitis - Pipeline by Coherus BioSciences Inc, H1 2017
  • Uveitis - Pipeline by Elasmogen Ltd, H1 2017
  • Uveitis - Pipeline by Endocyte Inc, H1 2017
  • Uveitis - Pipeline by Enzo Biochem Inc, H1 2017
  • Uveitis - Pipeline by EyeGate Pharmaceuticals Inc, H1 2017
  • Uveitis - Pipeline by Eyevensys SAS, H1 2017
  • Uveitis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Uveitis - Pipeline by HanAll Biopharma Co Ltd, H1 2017
  • Uveitis - Pipeline by Icon Bioscience Inc, H1 2017
  • Uveitis - Pipeline by Idera Pharmaceuticals Inc, H1 2017
  • Uveitis - Pipeline by InnoMedica Holding AG, H1 2017
  • Uveitis - Pipeline by KPI Therapeutics Inc, H1 2017
  • Uveitis - Pipeline by Midatech Pharma Plc, H1 2017
  • Uveitis - Pipeline by Mitotech SA, H1 2017
  • Uveitis - Pipeline by Nemus Bioscience Inc, H1 2017
  • Uveitis - Pipeline by Neuroptis Biotech, H1 2017
  • Uveitis - Pipeline by Novartis AG, H1 2017
  • Uveitis - Pipeline by Oculis ehf, H1 2017
  • Uveitis - Pipeline by OncoNOx ApS, H1 2017
  • Uveitis - Pipeline by Orchid Pharma Ltd, H1 2017
  • Uveitis - Pipeline by OSE Immunotherapeutics, H1 2017
  • Uveitis - Pipeline by Palatin Technologies Inc, H1 2017
  • Uveitis - Pipeline by Panacea Biotec Ltd, H1 2017
  • Uveitis - Pipeline by Panoptes Pharma GesmbH, H1 2017
  • Uveitis - Pipeline by Pfizer Inc, H1 2017
  • Uveitis - Pipeline by pSivida Corp, H1 2017
  • Uveitis - Pipeline by Re-Pharm Ltd, H1 2017
  • Uveitis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
  • Uveitis - Pipeline by Sandoz International GmbH, H1 2017
  • Uveitis - Pipeline by Santen Pharmaceutical Co Ltd, H1 2017
  • Uveitis - Pipeline by SynDevRx Inc, H1 2017
  • Uveitis - Pipeline by TxCell SA, H1 2017
  • Uveitis - Dormant Projects, H1 2017
  • Uveitis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Uveitis - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Uveitis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Uveitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top